Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Orphan Drug Wholesaler S.D. Next to Swing into Black in FY2015 with Tailored Distribution Services: Pres.
August 30, 2013
- WHO Grants Prequalification to Eisai for Lymphatic Filariasis Treatment
August 30, 2013
- New Products Shake Up Market for Osteoporosis Treatments; Entry of Pralia Could Lead to Change in Market Structure
August 30, 2013
- AnGes MG’s CIN Therapeutic Vaccine Project Picked for Health Ministry’s Research Grants
August 29, 2013
- Merck Serono’s Northeast Asian Development Zeros in on 4 Cancer Types: R&D Site Head
August 29, 2013
- Eisai Launches Higher-Dose Aricept 23 mg Tablet in South Korea
August 29, 2013
- Shionogi Paid a Total of 10.2 Billion Yen to Healthcare Professionals, 1 Billion for Research Grants
August 28, 2013
- Takeda Initiates Overseas PIII Trial of Actos for Delaying the Onset of MCI Due to Alzheimer’s Disease
August 28, 2013
- Takeda to Appoint Mr Roger as CFO
August 28, 2013
- Livalo AG Skips NHI Price Listing Again, Sandoz Won’t Comment on Diovan AG
August 27, 2013
- Astellas Launches Tacrolimus Extended-Release Capsules Astagraf XL in US
August 27, 2013
- LEO Pharma Files NDA for Psoriasis Drug, Paving Way for Full Foray into Japan Market
August 27, 2013
- Announcement: Oncology Japan 2013 to Be Held on November 5, 6
August 27, 2013
- Affinity Gel Market to Triple in 2017: Fuji Chimera Research Institute
August 26, 2013
- Somatropin BS SC Injection Approved for Full Range of Indications with Additional Indications: Sandoz
August 26, 2013
- Plavix, Diovan Rank 1st, 3rd in Japan Ethical Drugs Sales in April-June: IMS Japan
August 26, 2013
- Eisai Files Petition with US Court to Nudge DEA over Stalled Scheduling of Fycompa
August 23, 2013
- OrphanPacific to Launch Normosang, Second Ultra Orphan Drug, on Aug. 23
August 22, 2013
- Patent Cliff Hits Major Global Drug Makers, Weak Yen Weighs on Japan Sales
August 22, 2013
- Ajinomoto Obtains Approval for CCB Atelec Tab. 20
August 22, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…